Novo Nordisk A/S (BVMF:N1VO34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 986.69B -28.7% |
| Revenue (ttm) | 260.81B +5.6% |
| Net Income | 92.19B +4.8% |
| EPS | 20.74 +5.0% |
| Shares Out | n/a |
| PE Ratio | 10.70 |
| Forward PE | 14.37 |
| Dividend | 0.77 (2.74%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 6,634 |
| Open | 28.10 |
| Previous Close | 27.61 |
| Day's Range | 27.59 - 28.10 |
| 52-Week Range | 22.90 - 42.43 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.
Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl, she could s...
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated...
Novo's Sogroya Gets Positive EU Opinion For Children With Idiopathic Short Stature
(RTTNews) - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of once-weekly Sogroya (somapaci...
Orbis Medicines Partners With Novo In Up To $1.4 Billion Drug Discovery Deal
(RTTNews) - Privately held Orbis Medicines has entered a strategic collaboration and licensing agreement with Novo Nordisk (NVO) to discover and develop next-generation oral therapies for cardiometabo...
Is It Too Late to Buy Novo Nordisk AS (NVO) After 3.5% Rally? GF Value Says Undervalued
Is It Too Late to Buy Novo Nordisk AS (NVO) After 3.5% Rally? GF Value Says Undervalued
Novo Nordisk's hemophilia drug clears a key hurdle in Europe
Novo Nordisk's hemophilia drug clears a key hurdle in Europe
Novo Nordisk's FREHEMGO Gets Positive CHMP Opinion For Haemophilia A
(RTTNews) - Novo Nordisk A/S (NVO) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization ...
Novo Nordisk reports CHMP adopts positive opinion on MAA for Frehemgo
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Frehemgo t...
Novo Nordisk announces FRONTIER5 Phase 3b results for denecimig
Novo Nordisk (NVO) ‘announced that phase 3b results from the FRONTIER5 study of investigational denecimig were published in the Journal of Thrombosis and Haemostasis. The 26-week results showed that a...
Novo, Orbis sign up to $1.4 billion deal to develop oral drugs
Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditio...
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and dev...
Novo Nordisk Partners with Anthropic to Accelerate Drug Discovery
Novo Nordisk Partners with Anthropic to Accelerate Drug Discovery
This Trend is Excellent News for Eli Lilly and Its Investors
Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.
Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
Novo Nordisk has lost its lead in the weight loss market. The company could face even more competition going forward.
Novo (NVO) Partners with Anthropic on AI Drug Discoveries
Danish pharmaceutical giant Novo ($NVO) is partnering with startup Anthropic to advance drug discoveries using artificial intelligence (AI) technologies.
Novo Nordisk Scores Major AI Deal With World's Most Valuable AI Company
Novo Nordisk Scores Major AI Deal With World's Most Valuable AI Company
Novo partners with Anthropic to speed up drug development with Claude
Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said on Wednesday.
Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude
The companies said their collaboration aims to address key challenges in the drug-discovery process by developing targeted solutions and workflows.
Novo Nordisk announces collaboration with Anthropic
The company states: “Novo Nordisk (NVO) and Anthropic announced a collaboration that will help Novo accelerate the development of new medicines and advance AI-driven software development. The companie...
Novo Nordisk To Present Broad Semaglutide And Cardiometabolic Pipeline Data At EASD 2026
(RTTNews) - Novo Nordisk A/S (NVO) will present a wide range of real-world and clinical data across its cardiometabolic portfolio at the 62nd Annual Meeting of the European Association for the Study o...
Novo Nordisk Stock Falls After Major Rebrand
Novo Nordisk Stock Falls After Major Rebrand
Novo CEO urges staff to embrace more customer-focused culture
Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market.
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies. Regeneron Pharmaceuticals maintains a strong foothold in ophthalmolog...
Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why
Novo Nordisk shares ($NVO) fell by 1% to around $43 per share early Tuesday. This came even after the popular obesity drugmaker rebranded simply to ‘ Novo ‘ on Monday.